1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,160 | 1,220 | 14:51 | |
| 1,160 | 1,220 | 14:42 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | MIRA PHARMACEUTICALS, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 24.10. | MIRA Pharmaceuticals Initiates Multiple Ascending Dose Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication | 273 | ACCESS Newswire | Advancing toward Phase 2a clinical evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track consideration MIAMI, FLORIDA / ACCESS Newswire /... ► Artikel lesen | |
| 23.10. | MIRA PHARMACEUTICALS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 16.10. | Mira Pharmaceuticals stock soars after positive pain treatment study results | 12 | Investing.com | ||
| 16.10. | Morning Market Movers: rYojbaba, Linkage Global, MIRA Pharmaceuticals, Fossil Group See Big Swings | 472 | AFX News | LOWELL (dpa-AFX) - At 7:45 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 16.10. | MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain | 279 | ACCESS Newswire | Findings show oral Mira-55 fully normalized pain and significantly reduced inflammation, supporting IND plans and reinforcing MIRA's position in a $70 billion non-opioid pain market. MIAMI, FLORIDA... ► Artikel lesen | |
| 16.10. | Why Mira Pharmaceuticals Shares Rose 69% After Hours? | 24 | Benzinga.com | ||
| MIRA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 15.10. | MIRA PHARMACEUTICALS, INC. - 8-K, Current Report | 25 | SEC Filings | ||
| 30.09. | MIRA Pharmaceuticals schließt Übernahme von SKNY ab und stärkt Finanzposition durch 5 Millionen US-Dollar | 12 | Investing.com Deutsch | ||
| 30.09. | MIRA Pharmaceuticals completes acquisition of SKNY Pharmaceuticals | 3 | Investing.com | ||
| 30.09. | MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction | 261 | ACCESS Newswire | Closing adds $5 million in marketable securities, strengthens financial position, and complements MIRA's advancing programs including Ketamir-2 and MIRA-55 MIAMI, FLORIDA / ACCESS Newswire / September... ► Artikel lesen | |
| 30.09. | MIRA PHARMACEUTICALS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 22.09. | MIRA Pharmaceuticals reports positive Phase 1 results for pain drug | 7 | Investing.com | ||
| 22.09. | MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog | 197 | ACCESS Newswire | Study demonstrated Ketamir-2 was safe and well tolerated at all dose levels, with a favorable safety and tolerability profile, with no severe or clinically significant adverse effects observed. The... ► Artikel lesen | |
| 22.09. | MIRA PHARMACEUTICALS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 16.09. | MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals | 244 | ACCESS Newswire | MIRA advances Ketamir-2 in the clinic for neuropathic pain while broadening development into neuropsychiatric disorders such as PTSD MIAMI, FLORIDA / ACCESS Newswire / September 16, 2025 / MIRA Pharmaceuticals... ► Artikel lesen | |
| 12.09. | MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation | 310 | ACCESS Newswire | SKNY transaction strengthens MIRA pipeline with SKNY-1, a differentiated oral candidate that has demonstrated up to 30% weight loss and nicotine craving reversal in preclinical studies. MIAMI, FL /... ► Artikel lesen | |
| 11.09. | MIRA PHARMACEUTICALS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 19.08. | MIRA Pharmaceuticals schließt Phase-1-SAD-Studie für Schmerzmittel ab | 4 | Investing.com Deutsch | ||
| 19.08. | MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage | 478 | ACCESS Newswire | Following FDA IND clearance for neuropathic pain, the Company is preparing to initiate its U.S. Phase 2a trial in Q4 2025 MIAMI, FL / ACCESS Newswire / August 19, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA)... ► Artikel lesen |
1 2 3 Weiter >>
55 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 89,75 | +1,36 % | Frank Fischer (Shareholder Value): BioNTech & Co. mit neuem Schwung und Momentum | 10.11.2025 - Die Berichtssaison für das 3. Quartal ist in vollem Gange. US-Big-Techs wie Microsoft und Amazon haben starke Zahlen vorgelegt. Europa liegt über den Erwartungen. Und: Im Biotech-Bereich... ► Artikel lesen | |
| EVOTEC | 5,270 | +1,31 % | EQS-News: Evotec SE: Evotec erhält Meilenstein-Zahlung von Bristol Myers Squibb nach Zulassung eines IND-Antrags in der strategischen Partnerschaft im Bereich Protein Degradation | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec erhält Meilenstein-Zahlung von Bristol Myers Squibb nach Zulassung eines IND-Antrags in der strategischen Partnerschaft im... ► Artikel lesen | |
| BB BIOTECH | 45,550 | +0,66 % | BB Biotech im Aufwind - Zinswende treibt Biotech-Rally an | US-Zinssenkung belebt den Biotech-Sektor. BB Biotech glänzt mit starkem Quartal, vier Exits und klarer Outperformance gegenüber dem Nasdaq Biotech Index. Seit der ersten Zinssenkung der US-Notenbank... ► Artikel lesen | |
| QIAGEN | 38,490 | +1,95 % | AIM WINNERS & LOSERS: CelLBxHealth rises on Qiagen deal | ||
| CUREVAC | 4,484 | -1,15 % | HV-Termine: Hauptversammlungen bei artnet, BVB, Cherry, CureVac, Schloss Wachenheim, SDM, The Grounds | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| AMGEN | 296,40 | -0,24 % | Jim Cramer Says Amgen (AMGN)'s New Drug Has Good Data | ||
| NOVAVAX | 5,729 | +0,90 % | NOVAVAX INC steht still - ich rieche gewaltige Bewegung! | ||
| STRYKER | 310,20 | -0,06 % | Stryker VP, GM for Robotics and Enabling Technologies is departing | ||
| BIOGEN | 146,90 | +0,72 % | Biogen Inc.: Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments | - Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative... ► Artikel lesen | |
| ILLUMINA | 105,02 | -0,30 % | ILLUMINA, INC. - 8-K, Current Report | ||
| CRISPR THERAPEUTICS | 47,000 | +1,73 % | Crispr Therapeutics gains amid takeover speculation | ||
| AAP IMPLANTATE | 1,390 | -2,80 % | EQS-NVR: aap Implantate AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: aap Implantate AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
aap Implantate AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach §... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,670 | +1,83 % | Inovio Pharmaceuticals stock price target raised to $6 by Piper Sandler | ||
| OCUGEN | 0,990 | +0,16 % | Ocugen Provides Business Update with Third Quarter 2025 Financial Results | Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA)... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,360 | -1,13 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results | Held meeting with U.S. Food and Drug Administration (FDA) where, among other things, they reiterated October 2024 agreement to use estimated glomerular filtration rate (eGFR) slope as an endpoint... ► Artikel lesen |
MIRA PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -2,44 % bei einem Aktienkurs von 1,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MIRA PHARMACEUTICALS INC finden Sie auf Wallstreet Online.